1527 related articles for article (PubMed ID: 8600797)
1. p53 expression is rare in cutaneous melanomas.
Saenz-Santamaría MC; McNutt NS; Bogdany JK; Shea CR
Am J Dermatopathol; 1995 Aug; 17(4):344-9. PubMed ID: 8600797
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of p53 protein expression in Spitz nevus as compared with other melanocytic lesions.
Bergman R; Shemer A; Levy R; Friedman-Birnbaum R; Trau H; Lichtig C
Am J Dermatopathol; 1995 Dec; 17(6):547-50. PubMed ID: 8599466
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of BCL-2 in melanomas and intradermal nevi.
Saenz-Santamaría MC; Reed JA; McNutt NS; Shea CR
J Cutan Pathol; 1994 Oct; 21(5):393-7. PubMed ID: 7868749
[TBL] [Abstract][Full Text] [Related]
4. Expression of NM23 protein in acquired melanocytic nevi, malignant melanoma and metastases of malignant melanoma: an immunohistological assessment in human skin.
Reichrath J; Seyfried P; Braun R; Müller SM; Baum HP; Bahmer FA
Dermatology; 1997; 194(2):136-9. PubMed ID: 9094461
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutation and expression in naevi and melanomas.
Sparrow LE; Soong R; Dawkins HJ; Iacopetta BJ; Heenan PJ
Melanoma Res; 1995 Apr; 5(2):93-100. PubMed ID: 7620345
[TBL] [Abstract][Full Text] [Related]
6. MIB-1 immunoreactivity correlates with metastatic dissemination in primary thick cutaneous melanoma.
Böni R; Doguoglu A; Burg G; Müller B; Dummer R
J Am Acad Dermatol; 1996 Sep; 35(3 Pt 1):416-8. PubMed ID: 8784279
[TBL] [Abstract][Full Text] [Related]
7. Prognostic implications of p53 overexpression in cutaneous melanoma from sun-exposed and nonexposed sites.
Essner R; Kuo CT; Wang H; Wen DR; Turner RR; Nguyen T; Hoon DS
Cancer; 1998 Jan; 82(2):309-16. PubMed ID: 9445187
[TBL] [Abstract][Full Text] [Related]
8. Proliferative activity of primary cutaneous melanocytic tumours.
Kuwata T; Kitagawa M; Kasuga T
Virchows Arch A Pathol Anat Histopathol; 1993; 423(5):359-64. PubMed ID: 7906909
[TBL] [Abstract][Full Text] [Related]
9. Patterns of cell proliferation in actinic keratoacanthomas and squamous cell carcinomas of the skin. Immunohistochemical study using the MIB 1 antibody in formalin-fixed paraffin sections.
Skálová A; Michal M
Am J Dermatopathol; 1995 Aug; 17(4):332-4. PubMed ID: 8600794
[TBL] [Abstract][Full Text] [Related]
10. Mutation and expression of TP53 in malignant melanomas.
Weiss J; Heine M; Arden KC; Körner B; Pilch H; Herbst RA; Jung EG
Recent Results Cancer Res; 1995; 139():137-54. PubMed ID: 7597286
[TBL] [Abstract][Full Text] [Related]
11. p53 and mdm-2 expression in malignant melanoma: an immunocytochemical study of expression of p53, mdm-2, and markers of cell proliferation in primary versus metastatic tumors.
Gelsleichter L; Gown AM; Zarbo RJ; Wang E; Coltrera MD
Mod Pathol; 1995 Jun; 8(5):530-5. PubMed ID: 7675773
[TBL] [Abstract][Full Text] [Related]
12. Expression of p53 protein in oral squamous cell carcinomas and adjacent non-tumorous mucosa of the floor of the mouth: an archival immunohistochemical study using wet autoclave pretreatment for antigen retrieval.
Piffkó J; Bánkfalvi A; Ofner D; Berens A; Tkotz T; Joos U; Böcker W; Schmid KW
J Oral Pathol Med; 1995 Sep; 24(8):337-42. PubMed ID: 7500288
[TBL] [Abstract][Full Text] [Related]
13. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
14. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
15. Determination of proliferating fractions in malignant melanomas by anti-PCNA/cyclin monoclonal antibody.
Takahashi H; Strutton GM; Parsons PG
Histopathology; 1991 Mar; 18(3):221-7. PubMed ID: 1675189
[TBL] [Abstract][Full Text] [Related]
16. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.
Hofbauer GF; Kamarashev J; Geertsen R; Böni R; Dummer R
Melanoma Res; 1998 Aug; 8(4):337-43. PubMed ID: 9764809
[TBL] [Abstract][Full Text] [Related]
17. RT in situ PCR detection of MART-1 and TRP-2 mRNA in formalin-fixed, paraffin-embedded tissues of melanoma and nevi.
Itakura E; Huang RR; Wen DR; Paul E; Wünsch PH; Cochran AJ
Mod Pathol; 2008 Mar; 21(3):326-33. PubMed ID: 18204435
[TBL] [Abstract][Full Text] [Related]
18. DNA mismatch repair enzyme hMSH2 in malignant melanoma: increased immunoreactivity as compared to acquired melanocytic nevi and strong mRNA expression in melanoma cell lines.
Rass K; Gutwein P; Welter C; Meineke V; Tilgen W; Reichrath J
Histochem J; 2001 Aug; 33(8):459-67. PubMed ID: 11931386
[TBL] [Abstract][Full Text] [Related]
19. Aberrant DNA methylation silences the novel heat shock protein H11 in melanoma but not benign melanocytic lesions.
Sharma BK; Smith CC; Laing JM; Rucker DA; Burnett JW; Aurelian L
Dermatology; 2006; 213(3):192-9. PubMed ID: 17033167
[TBL] [Abstract][Full Text] [Related]
20. Morphometric, DNA, and proliferating cell nuclear antigen measurements in benign melanocytic lesions and cutaneous malignant melanoma.
Björnhagen V; Bonfoco E; Brahme EM; Lindholm J; Auer G
Am J Dermatopathol; 1994 Dec; 16(6):615-23. PubMed ID: 7864299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]